Acute cardiac care & resuscitation
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock
PerformanceResult — go to the resultAdjusted hazard ratio 1.06 95% CI 1.03–1.09Authors' conclusion
Plasma proteomic screening identified VEGFR1 as an early biomarker in patients with AMICS that provided independent prognostic information in a large cohort of well-defined patients with AMICS.
Study context
- Population
- Patients with cardiogenic shock complicating acute MI (AMICS)validation cohort
- Participants
- 421 patients
- Comparison
- VEGFR1 levels in nonsurvivors vs survivors of acute myocardial infarction (AMI)-related cardiogenic shock
- Outcome
- 180-day survival
- Follow-up
- 180 days
Methodological detailsproteomic discovery with cohort validation, exploration cohort, independent validation cohort (CULPRIT-SHOCK), third serial-measurement cohort
- Proteomic discovery with cohort validation
- Exploration cohort
- Independent validation cohort (CULPRIT-SHOCK)
- Third serial-measurement cohort
Performance
As reported in the abstract
Adjusted hazard ratio
1.06
95% CI 1.03–1.09
P < 0.001
By group
VEGFR1 (per ng/L)
adjusted HR 1.06 (95% CI 1.03–1.09); P < 0.001
Per ng/L, as printed
- Incremental prognostic information in addition to serum lactate
- P < 0.001
Further findings
Proteome screening, exploration cohort (9 AMI without shock vs 8 AMICS) · admission
- Profiling successful for 2925 proteins; VEGFR1 elevated in AMICS vs nonshock AMI
- P < 0.001
Serial VEGFR1, third cohort (30-day survivors n=29, nonsurvivors n=21; days 0, 1, 5)
- Continuously higher VEGFR1 levels in nonsurvivors
Original publication
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock. Circ Heart Fail. Published 1 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →